The use of remote patient monitoring (RPM) and decentralised clinical trials (DCTs) have surged as the industry started using these strategies to tackle the COVID-19-induced clinical trial disruptions.

GlobalData conducted a survey to identify how the pharmaceutical and healthcare industry is addressing clinical trial disruptions amid the pandemic.

Remote patient monitoring and decentralised clinical trials emerge as dominant strategies to counter clinical trial disruptionsAddressing Clinical Trial Disruptions Related to the COVID-19 Outbreak

According to the survey results, 17% of the respondents adopted RPM to address clinical trial disruptions, while another 15% intend to switch to DCTs.

Approximately 14% voted for remote site initiation visits, while 13% of the companies asked research staff to work remotely.

Direct-to-patient (DTP) drug delivery was selected by 11% of the respondents.

Among the respondents, 9% halted screening and/ or enrolment for all clinical trials due to the pandemic situation and another 7% completely ceased opening any new trials.

Around 7% of the surveyed companies prioritised enrolment for certain clinical trials.

The remaining 7% respondents implemented remote safety lab collections.

The analysis is based on responses received for the Coronavirus Disease 2019 (COVID-19) Sector Impact: The COVID-19 Pandemic Impact on Clinical Trials survey conducted by GlobalData between 04 June and 22 June 2020.